Assessing the benefit–risk of new treatments using generalised pairwise comparisons: the case of erlotinib in pancreatic cancer

BACKGROUND: Efficacy and safety are the two considerations when characterising the effects of a new therapy. We sought to apply an innovative method of assessing the benefit–risk balance using data from a completed randomised controlled trial that compared erlotinib vs placebo added to gemcitabine i...

Descripción completa

Detalles Bibliográficos
Autores principales: Péron, J, Roy, P, Ding, K, Parulekar, W R, Roche, L, Buyse, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4366896/
https://www.ncbi.nlm.nih.gov/pubmed/25688740
http://dx.doi.org/10.1038/bjc.2015.55

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4366896/
https://www.ncbi.nlm.nih.gov/pubmed/25688740
http://dx.doi.org/10.1038/bjc.2015.55

Ejemplares similares